A Phase Ib/II, Open-label, Single Arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Bulumtatug Furvedotin (Primary) ; Toripalimab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- Sponsors Mabwell (Shanghai) Bioscience
Most Recent Events
- 05 Jun 2025 According to a Mabwell (Shanghai) Bioscience media release, data from the trial were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, from May 30 to June 3
- 05 Jun 2025 Results (As of Apr. 30, 2025, n=52) presented in the Mabwell Media Release
- 23 May 2025 Results published in the Mabwell (Shanghai) Bioscience Media Release